Czechia· CZ-0268692
HYMPAVZI
A marstacimab product containing marstacimab, registered in Czechia by Pfizer Europe MA EEIG, Bruxelles. The same ATC class is registered in 11 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Marstacimab is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BX11 (marstacimab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Marstacimab · ATC B02BX11
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- MARSTACIMAB
- Manufacturer
- Pfizer Europe MA EEIG, Bruxelles
- Country
- Czechia (CZ)
- ATC code
- B02BX11
- ATC class
- Marstacimab
- Defined daily dose
- 21 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02686921X1MLCZK 167606.52
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Marstacimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandHympavziPfizer Europe MA EEIG*
- SwedenHympavzi 150 mg Injektionsvätska, lösning i förfylld injektionspennaPfizer Europe MA EEIG
- BelgiumHympavzi 150 mgPfizer Europe MA
- United KingdomHympavzi 150mg/1ml solution for injection pre-filled pensPfizer Ltd
- SpainHYMPAVZI 150 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAPfizer Europe Ma Eeig
- NorwayHympavziPfizer Europe MA EEIG
- United StatesHYMPAVZIPfizer Laboratories Div Pfizer Inc
- IrelandHympavzi 150 mg solution for injection in pre-filled penPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hympavzi
- Liechtenstein · Hympavzi
- Norway · Hympavzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2d4a070-d282-4758-a240-d3074ddeae92 GET /v1/drugs/e2d4a070-d282-4758-a240-d3074ddeae92?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL PEP",
"source": "sukl",
"strength": "150MG",
"pack_size": "1X1ML",
"substance": "MARSTACIMAB",
"cz_kod_sukl": "0268692",
"product_type": "BT",
"substance_codes": "21952",
"registration_state": "R",
"registration_number": "EU/1/24/1874/002"
}See everything about marstacimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.